In last trading session, Aclaris Therapeutics Inc (NASDAQ:ACRS) saw 1.4 million shares changing hands with its beta currently measuring 0.47. Company’s recent per share price level of $3.08 trading at -$0.18 or -5.52% at ring of the bell on the day assigns it a market valuation of $220.00M. That closing price of ACRS’s stock is at a discount of -67.86% from its 52-week high price of $5.17 and is indicating a premium of 74.03% from its 52-week low price of $0.80. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.89 million shares which gives us an average trading volume of 2.30 million if we extend that period to 3-months.
For Aclaris Therapeutics Inc (ACRS), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.57. Splitting up the data highlights that, out of 4 analysts covering the stock, 1 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 3 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.33 in the current quarter.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Aclaris Therapeutics Inc (NASDAQ:ACRS) trade information
Upright in the red during last session for losing -5.52%, in the last five days ACRS remained trading in the red while hitting it’s week-highest on Thursday, 12/12/24 when the stock touched $3.08 price level, adding 13.73% to its value on the day. Aclaris Therapeutics Inc’s shares saw a change of 193.33% in year-to-date performance and have moved -12.99% in past 5-day. Aclaris Therapeutics Inc (NASDAQ:ACRS) showed a performance of -1.91% in past 30-days. Number of shares sold short was 2.48 million shares which calculate 0.47 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 7 to the stock, which implies a rise of 56.0% to its current value. Analysts have been projecting 3 as a low price target for the stock while placing it at a high target of 8. It follows that stock’s current price would jump 2.6% in reaching the projected high whereas dropping to the targeted low would mean a gain of 2.6% for stock’s current value.
Aclaris Therapeutics Inc (ACRS) estimates and forecasts
Statistics highlight that Aclaris Therapeutics Inc is scoring comparatively higher than the scores of other players of the relevant industry. The company added 172.57% of value to its shares in past 6 months, showing an annual growth rate of 46.45% while that of industry is 16.80. Apart from that, the company came raising its revenue forecast for fiscal year 2024. This year revenue growth is estimated to fall -47.81% from the last financial year’s standing.
7 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 6.23M for the same. And 4 analysts are in estimates of company making revenue of 2.71M in the next quarter. Company posted 17.57M and 2.4M of sales in current and next quarters respectively a year earlier.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 20.67% during past 5 years.
Aclaris Therapeutics Inc (NASDAQ:ACRS)’s Major holders
Insiders are in possession of 3.65% of company’s total shares while institution are holding 90.21 percent of that, with stock having share float percentage of 93.63%. Investors also watch the number of corporate investors in a company very closely, which is 90.21% institutions for Aclaris Therapeutics Inc that are currently holding shares of the company. BML CAPITAL MANAGEMENT, LLC is the top institutional holder at ACRS for having 12.99 million shares of worth $14.29 million. And as of 2024-06-30, it was holding 18.2739 of the company’s outstanding shares.
The second largest institutional holder is VANGUARD GROUP INC, which was holding about 4.69 million shares on 2024-06-30. The number of shares represents firm’s hold over 6.5952 of outstanding shares, having a total worth of $5.16 million.
